Paper39620653
Crovalimab in the paroxysmal nocturnal hemoglobinuria treatment landscape.
Röth A and 3 others. Immunotherapy, 2024. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. Crovalimab in the paroxysmal nocturnal hemoglobinuria treatment landscape. Papers, record 39620653. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39620653
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Hemoglobinuria, Paroxysmal | Major topic |
| Complement C5 | Major topic |
| Antibodies, Monoclonal, Humanized | Major topic |
| Complement Inactivating Agents | Major topic |
| Humans |
Source PubMed
References54
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37321625 | Crovalimab treatment in patients with paroxysmal nocturnal haemoglobinuria: Long-term results from the phase I/II COMPOSER trial. | Eur J Haematol | 2023 | https://conductscience.org/library/papers/37321625 | PubMed |
| 2 | 20824457 | Epidemiology of rare anaemias in Europe. | Adv Exp Med Biol | 2010 | https://conductscience.org/library/papers/20824457 | PubMed |
| 3 | 32713742 | Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria. | Hematol Transfus Cell Ther | 2021 | https://conductscience.org/library/papers/32713742 | PubMed |
| 4 | 30171728 | Diagnosis and management of PNH: Review and recommendations from a Belgian expert panel. | Eur J Haematol | 2018 | https://conductscience.org/library/papers/30171728 | PubMed |
| 5 | 35608260 | Crovalimab for treatment of patients with paroxysmal nocturnal haemoglobinuria and complement C5 polymorphism: Subanalysis of the phase 1/2 COMPOSER study. | Br J Haematol | 2022 | https://conductscience.org/library/papers/35608260 | PubMed |
| 6 | 39535306 | Safety of Crovalimab Versus Eculizumab in Patients With Paroxysmal Nocturnal Haemoglobinuria (PNH): Pooled Results From the Phase 3 COMMODORE Studies. | Eur J Haematol | 2025 | https://conductscience.org/library/papers/39535306 | PubMed |
| 7 | 37421604 | Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single-arm study. | Am J Hematol | 2023 | https://conductscience.org/library/papers/37421604 | PubMed |
| 8 | 37655691 | The cost-effectiveness of pegcetacoplan in complement treatment-naïve adults with paroxysmal nocturnal hemoglobinuria in the USA. | J Comp Eff Res | 2023 | https://conductscience.org/library/papers/37655691 | PubMed |
| 9 | 24161035 | Overview of complement activation and regulation. | Semin Nephrol | 2013 | https://conductscience.org/library/papers/24161035 | PubMed |
| 10 | 18055865 | Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. | Blood | 2008 | https://conductscience.org/library/papers/18055865 | PubMed |
| 11 | 37405515 | Clinically important change for the FACIT-Fatigue scale in paroxysmal nocturnal hemoglobinuria: a derivation from international PNH registry patient data. | J Patient Rep Outcomes | 2023 | https://conductscience.org/library/papers/37405515 | PubMed |
| 12 | 28439081 | Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases. | Sci Rep | 2017 | https://conductscience.org/library/papers/28439081 | PubMed |
| 13 | 28516949 | Paroxysmal nocturnal haemoglobinuria. | Nat Rev Dis Primers | 2017 | https://conductscience.org/library/papers/28516949 | PubMed |
| 14 | 30510079 | Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. | Blood | 2019 | https://conductscience.org/library/papers/30510079 | PubMed |
| 15 | 36848639 | Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria. | Blood Adv | 2023 | https://conductscience.org/library/papers/36848639 | PubMed |
| 16 | 31258525 | Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT. | Front Immunol | 2019 | https://conductscience.org/library/papers/31258525 | PubMed |
| 17 | 36594182 | Paroxysmal nocturnal hemoglobinuria: Where we stand. | Am J Hematol | 2023 | https://conductscience.org/library/papers/36594182 | PubMed |
| 18 | 38924124 | Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria. | Am J Hematol | 2024 | https://conductscience.org/library/papers/38924124 | PubMed |
| 19 | 21460245 | Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. | Blood | 2011 | https://conductscience.org/library/papers/21460245 | PubMed |
| 20 | 26839475 | Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a Korean PNH Registry. | J Korean Med Sci | 2016 | https://conductscience.org/library/papers/26839475 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41809517 | Optimizing Care in Patients with Paroxysmal Nocturnal Hemoglobinuria: Managing Suboptimal Response and Uncontrolled Disease. | J Blood Med | 2026 | https://conductscience.org/library/papers/41809517 | PubMed |
| 41503194 | Crovalimab Rescue Therapy in a Case With Genetic Complement Mediated Thrombotic Microangiopathy. | Kidney Med | 2026 | https://conductscience.org/library/papers/41503194 | PubMed |
| 41255851 | Advances in Complement Inhibition Therapies for Paroxysmal Nocturnal Hemoglobinuria and Autoimmune Hemolytic Disorders. | J Blood Med | 2025 | https://conductscience.org/library/papers/41255851 | PubMed |
| 40868216 | Monoclonal Antibodies (mAbs) and Proteins: The Biologic Drugs Approved by the Food and Drug Administration (FDA) in 2024. | Biomedicines | 2025 | https://conductscience.org/library/papers/40868216 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39620653
GET https://conductscience.org/api/papers/v1/39620653/references?page=2